Cargando…

Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years

Natalizumab (NTZ) has been used for treatment of highly active relapsing–remitting multiple sclerosis (MS). When stopping NTZ the risk of severe rebound phenomenon has to be considered. We aimed to investigate the use of NTZ in clinical routine and focused on identification of potential risk factors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Auer, Michael, Zinganell, Anne, Hegen, Harald, Bsteh, Gabriel, Di Pauli, Franziska, Berek, Klaus, Fava, Elena, Wurth, Sebastian, Berger, Thomas, Deisenhammer, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639988/ https://www.ncbi.nlm.nih.gov/pubmed/34857795 http://dx.doi.org/10.1038/s41598-021-02665-6

Ejemplares similares

Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study
por: Berek, Klaus, et al.
Publicado: (2021)

Retinal layer thinning is reflecting disability progression independent of relapse activity in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Serum hepcidin levels in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2019)

Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2019)

Impact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis
por: Hegen, Harald, et al.
Publicado: (2018)

Retinal layer thinning predicts treatment failure in relapsing multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2021)

SARS-CoV2 infection as a potential trigger for severe relapse in a patient with multiple sclerosis who stopped disease modifying treatment due to COVID-19 pandemic
por: Auer, Michael, et al.
Publicado: (2021)

Influence of physical activity on serum vitamin D levels in people with multiple sclerosis
por: Bauer, Angelika, et al.
Publicado: (2020)

Inner nuclear layer and olfactory threshold are interlinked and reflect inflammatory activity in multiple sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity
por: Berek, Klaus, et al.
Publicado: (2021)

Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi
por: Berek, Klaus, et al.
Publicado: (2020)

Recovery of Chronic Inflammatory Demyelinating Polyneuropathy on Treatment With Ocrelizumab in a Patient With Co-Existing Multiple Sclerosis
por: Auer, Michael, et al.
Publicado: (2022)

Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity—a cohort study
por: Hegen, Harald, et al.
Publicado: (2023)

Cerebrospinal fluid protein in Guillain–Barré syndrome: Need for age‐dependent interpretation
por: Hegen, Harald, et al.
Publicado: (2020)

Smoking is not associated with higher prevalence of JC virus in MS patients
por: Auer, Michael, et al.
Publicado: (2018)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Varicella Zoster Virus Infection - Frequency of an Association
por: Di Pauli, Franziska, et al.
Publicado: (2021)

Impairment of odor discrimination and identification is associated with disability progression and gray matter atrophy of the olfactory system in MS
por: Bsteh, Gabriel, et al.
Publicado: (2019)

Multiple sclerosis and COVID‐19: How many are at risk?
por: Bsteh, Gabriel, et al.
Publicado: (2020)

Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study
por: Wurth, Sebastian, et al.
Publicado: (2017)

Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study
por: Hegen, Harald, et al.
Publicado: (2017)

Immune profiling in multiple sclerosis: a single-center study of 65 cytokines, chemokines, and related molecules in cerebrospinal fluid and serum
por: Berek, Klaus, et al.
Publicado: (2023)

Paroxysmal and unusual symptoms as first clinical manifestation of multiple sclerosis do not indicate benign prognosis—The PaSiMS II study
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study
por: Bsteh, Gabriel, et al.
Publicado: (2016)

Longitudinal ventricular cerebrospinal fluid profile in patients with spontaneous subarachnoid hemorrhage
por: Zinganell, Anne, et al.
Publicado: (2022)

Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis—from diagnosis to prediction of disease activity
por: Hegen, Harald, et al.
Publicado: (2022)

Conversion and reversion of anti‐John Cunningham virus antibody serostatus: A prospective study
por: Auer, Michael, et al.
Publicado: (2019)

The clinical significance of single or double bands in cerebrospinal fluid isoelectric focusing. A retrospective study and systematic review
por: Hegen, Harald, et al.
Publicado: (2019)

Diagnostic Performance of Adding the Optic Nerve Region Assessed by Optical Coherence Tomography to the Diagnostic Criteria for Multiple Sclerosis
por: Bsteh, Gabriel, et al.
Publicado: (2023)

Estimating Risk of Multiple Sclerosis Disease Reactivation in Pregnancy and Postpartum: The VIPRiMS Score
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023)

Correction: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR)
por: Monschein, Tobias, et al.
Publicado: (2023)

Utility of Two-Dimensional Difference Gel Electrophoresis in Diagnosis of Multiple Sclerosis
por: Auer, Michael, et al.
Publicado: (2018)

‘No evidence of disease activity’ – is it an appropriate surrogate in multiple sclerosis?
por: Hegen, H., et al.
Publicado: (2018)

Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis
por: Ehling, Rainer, et al.
Publicado: (2011)

Humoral Response to SARS-CoV-2 Antigen in Patients Treated with Monoclonal Anti-CD20 Antibodies: It Is Not All about B Cell Recovery
por: Feige, Julia, et al.
Publicado: (2022)

Comparing humoral immune response to SARS‐CoV2 vaccines in people with multiple sclerosis and healthy controls: An Austrian prospective multicenter cohort study
por: Bsteh, Gabriel, et al.
Publicado: (2022)

Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: A prospective multicenter study
por: Krajnc, Nik, et al.
Publicado: (2022)

Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc
por: Bsteh, Gabriel, et al.
Publicado: (2017)

Decision making and framing effects in multiple sclerosis
por: Zamarian, Laura, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2ooukv54j7vh9lojhbe037dndu